Skip to content

Low-dose Combination of Three Antihypertensive Drugs

Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial)

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02710552
Acronym
3D
Enrollment
100
Registered
2016-03-16
Start date
2016-04-30
Completion date
2020-03-31
Last updated
2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hypertension

Keywords

arterial hypertension, antihypertensive drugs

Brief summary

The aim of the study is to compare the efficacy and safety of low-dose combination of three antihypertensive drugs versus fixed high-dose combination of two antihypertensive drugs in arterial hypertension

Detailed description

The aim of the study is to compare the efficacy and safety of commercially available low-dose combination of three antihypertensive drugs versus commercially available fixed high-dose combination of two antihypertensive drugs in arterial hypertension

Interventions

Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg

DRUGReaptan (perindopril, amlodipine)

Fixed combination of perindopril 10 mg and amlodipine 5 mg

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients with arterial hypertension resistant to monotherapy

Exclusion criteria

None

Design outcomes

Primary

MeasureTime frameDescription
Number of patients who reach target blood pressureFrom baseline to the end of the 3-month study periodHow many patients have blood pressure within normal limits

Countries

Italy

Contacts

Primary ContactFrancesco Pelliccia, MD
md4151@mclink.it390649971
Backup ContactCesare Greco, MD
md4151@mclink.it390649971

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026